Dr. James Bristol appointed to board of Eterna Therapeutics

Ernexa Therapeutics Inc.

Dr. James Bristol appointed as director effective Oct 30, 2023; term until 2024 annual meeting.
Bristol appointed to Audit, Compensation, and Nominating/Corporate Governance Committees.
Board determined Bristol is independent under Nasdaq rules; no material transactions with the Company.
Standard non-employee director compensation and indemnification agreement to be entered into.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. James Bristol

director

ERNA · Ernexa Therapeutics Inc.

Effective: 2023-10-30
Filed: November 1, 2023, 7:59 PM ET

On October 30, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Dr. James Bristol as a director, effective on October 30, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. James Bristol was appointed as director at Ernexa Therapeutics Inc..

Action: appointed
Role: director

Exact text from the filing

On October 30, 2023, the Board of Directors (the “Board”) of Eterna Therapeutics Inc. (the “Company”) appointed Dr. James Bristol as a director, effective on October 30, 2023.

View on SEC.gov

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-050682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.